Heart patients get stronger combo pill after stent surgery
NCT ID NCT05782777
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether taking ezetimibe along with a high-dose statin (atorvastatin) works better than the statin alone for people who have had a heart stent placed. About 4,300 participants will be followed for three years to see if the combination reduces deaths, heart attacks, strokes, or the need for more procedures. The goal is to lower LDL cholesterol more aggressively and improve long-term heart health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ezetimibe and atorvastatin (combination therapy) versus atorvastatin alone
- What this could lead to
- If it works, this could show that adding ezetimibe to a high-dose statin reduces the risk of heart attacks, strokes, and death after stent placement.
- What could go wrong
- This is a large but early-stage trial with no phase designation. The benefit may be small or not outweigh the risks of side effects like muscle pain or liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 4,310 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2023
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 19-85 years 2. Patients who underwent coronary revascularization with newer generation DES implantation Exclusion Criteria: 1. Allergy or hypersensitive to ezetimibe or statin 2. Active liver disease or persistent unexplained serum AST/ALT elevation more than 2 times the upper limit of normal range 3. History of any adverse drug reaction requiring discontinuation of statin 4. Pregnant women, women with potential childbearing, or lactating women 5. Life expectancy less than 3 years 6. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator 7. Inability to understand or read the informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronary artery disease requiring coronary revascularization with newer generation des implantation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea